News Release, 25.01.2021 on EurekAlert! and Medical Press
Salzburger Nachrichten and Kleine Zeitung, 26.01.2021
G3BP proteins inhibit the metabolic driver MTOR, a signaling protein that plays a central role in tumor diseases and developmental disorders of the brain. This is reported in this week´s issue of the journal Cell. The study was led by scientists from the University of Innsbruck and the German Cancer Research Center together with the Medical University of Innsbruck and a European network.
Zukunft Forschung – Das Magazin für Wissenschaft und Forschung der Universität Innsbruck.
For the second time, the “German Tuberous Sclerosis Foundation” has awarded the 10,000-Euro prize for research. This year, the prize was awarded to the scientist and head of the Laboratory for Metabolic Signaling Prof. Dr. Kathrin Thedieck. Prof. Thedieck works at the University Medical Center Groningen (UMCG) and the European Medical School Oldenburg-Groningen (EMS), jointly led by the universities of Oldenburg and Groningen. The recipient was selected by an expert jury chaired by the chairman of the board of the Charité Berlin, Prof. Dr. Carl Max Einhäupl. The award ceremony was held by Prof. Dr. Carl Max Einhäupl together with the founders of the German Tuberous Sclerosis Foundation, Anke Koch and her husband Roland Koch, former Prime Minister of Hessen, and today’s Chairman of UBS Europe SE. Both had decided in 2012 to strengthen their commitment in the fight against tuberous sclerosis and therefore found the Tuberous Sclerosis Foundation.